These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 421232)
1. Cytotoxic effects of the lysosomotropic agents DNA-ellipticine, DNA-daunorubicin, and DNA-ellipticine:daunorubicin on L1210 leukemia cells. Sorace RA; Sheid B Cancer Treat Rep; 1979 Jan; 63(1):43-51. PubMed ID: 421232 [No Abstract] [Full Text] [Related]
2. Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells. Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR Cancer Res; 1980 Jul; 40(7):2390-9. PubMed ID: 6155993 [TBL] [Abstract][Full Text] [Related]
3. Ellipticine, 9-hydroxyellipticine, and 9-hydroxyellipiticinum: some biochemical properties of possible pharmacologic significance. Paoletti C; Auclair C; Lesca P; Tocanne JF; Malvy C; Pinto M Cancer Treat Rep; 1981; 65 Suppl 3():107-18. PubMed ID: 7049365 [TBL] [Abstract][Full Text] [Related]
4. Ellipticine and derivatives induce breakage of L1210 cells DNA in vitro. Paoletti C; Lesca C; Cros S; Malvy C; Auclair C Biochem Pharmacol; 1979; 28(3):345-50. PubMed ID: 426849 [No Abstract] [Full Text] [Related]
5. [Syntheses designed to produce 8-amino ellipticine. Synthesis and pharmacological properties of 8-nitro ellipticine]. Gansser C; Lévque X; Plat M; Viel C Farmaco Sci; 1982 May; 37(5):283-97. PubMed ID: 7095141 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of ellipticine and aza-analogue derivatives on cell cycle progression and survival of BALB/c 3T3 cells released from serum starvation or thymidine double block. Vilarem MJ; Charcosset JY; Primaux F; Gras MP; Calvo F; Larsen CJ Cancer Res; 1985 Aug; 45(8):3906-11. PubMed ID: 4016757 [TBL] [Abstract][Full Text] [Related]
7. Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Zwelling LA; Michaels S; Kerrigan D; Pommier Y; Kohn KW Biochem Pharmacol; 1982 Oct; 31(20):3261-7. PubMed ID: 7150355 [No Abstract] [Full Text] [Related]
8. [Sanguinarine and ellipticine cytotoxic alkaloids isolated from well-known antitumor plants. Intracellular targets of their action]. Faddeeva MD; Beliaeva TN Tsitologiia; 1997; 39(2-3):181-208. PubMed ID: 9312909 [TBL] [Abstract][Full Text] [Related]
9. Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine. Ross WE; Smith MC Biochem Pharmacol; 1982 May; 31(10):1931-5. PubMed ID: 7104026 [TBL] [Abstract][Full Text] [Related]
10. Binding to DNA, cellular uptake and biological activity of a distamycin-ellipticine hybrid molecule. Bailly C; Leclere V; Pommery N; Colson P; Houssier C; Rivalle C; Bisagni E; Hénichart JP Anticancer Drug Des; 1993 Apr; 8(2):145-64. PubMed ID: 8494604 [TBL] [Abstract][Full Text] [Related]
11. Effects of deoxyribonucleic acid-reactive drugs on ribonucleic acid synthesis in leukemia L1210 cells. Kann HE; Kohn KW Mol Pharmacol; 1972 Sep; 8(5):551-60. PubMed ID: 4117298 [No Abstract] [Full Text] [Related]
12. Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia. Edelstein M; Valeriote F; Vietti T Cancer Treat Rep; 1978 Apr; 62(4):547-8. PubMed ID: 657151 [No Abstract] [Full Text] [Related]
13. Effects of 9-OH-ellipticine on cell survival, macromolecular syntheses, and cell cycle progression in sensitive and resistant Chinese hamster lung cells. Charcosset JY; Bendirdjian JP; Lantieri MF; Jacquemin-Sablon A Cancer Res; 1985 Sep; 45(9):4229-36. PubMed ID: 2992775 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Meriwether WD; Bachur NR Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814 [No Abstract] [Full Text] [Related]
16. Interrelationship between affinity for DNA, cytotoxicity and induction of DNA-breaks in cultured L1210 cells for two series of tricyclic intercalators. Simplified analogues of ellipticine derivatives. Pierson V; Pierre A; de Cointet P; Nguyen CH; Bisagni E; Gros P Biochem Pharmacol; 1989 May; 38(9):1395-406. PubMed ID: 2719718 [TBL] [Abstract][Full Text] [Related]
17. Quantitative description of morphologic changes effected by antileukemic agents in L1210 leukemia cells. Iwasaki H; Liu YP; Nojyo Y; Ueda T; Nakamura T Anticancer Res; 1995; 15(1):133-9. PubMed ID: 7733623 [TBL] [Abstract][Full Text] [Related]
18. Influence of inducers of monooxygenases on cytotoxic efficiency of ellipticine on leukemia L1210 cells. Lesca P; Monsarrat B; Cros S; Paoletti C J Natl Cancer Inst; 1981 Oct; 67(4):871-6. PubMed ID: 6944554 [TBL] [Abstract][Full Text] [Related]
19. [Interactions between X-rays and antimitotic drugs: cellular effects (author's transl)]. Laval F; Carde P; Michel S Bull Cancer; 1981; 68(2):116-20. PubMed ID: 7195291 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: comparison with adriamycin and 4'-(9-acridinylamino)methanesulfon-m-anisidide. Zwelling LA; Kerrigan D; Michaels S Cancer Res; 1982 Jul; 42(7):2687-91. PubMed ID: 6896293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]